Peptide entry

Tirzepatide

Approved drugPeptide

Also known as: Mounjaro molecule, Zepbound molecule

Quick facts

Category
Weight Loss
Primary goal
Fat Loss (Beginner), Fat Loss (Advanced)
Dose pattern
Weekly, titrated
Treatment style
Titrated
Status
Approved drug
Vial formats
10 mg

Evidence / context

Evidence: Strong approved-drug evidence exists for the molecule; formulation and indication matter.

Available vial formats

Tirzepatide

10 mg
Mix 3.0 mLConcentration 3.333 mg/mL

Titration schedule

Full ramp to 15 mg weekly

Approved-label adult dose-escalation and maintenance context.

StageWeekly amountU-100 draw
Weeks 1-42.5 mg once weekly75 units
Weeks 5-85 mg once weekly150 units
Weeks 9-127.5 mg once weekly225 units
Weeks 13-1610 mg once weekly300 units
Weeks 17-2012.5 mg once weekly375 units
Week 21+15 mg once weekly - maintenance450 units

A calculated dose above 100 units exceeds one 100-unit U-100 syringe at this concentration. Use an appropriate multi-draw plan and verify the full dose.

A dose above 10 mg requires more than one selected 10 mg vial. A 15 mg dose cannot come from a single 10 mg vial.

Escalation / hold

Escalation is not automatic. Hold the current dose longer when tolerability requires it. The 2.5 mg dose is for initiation; 7.5 mg and 12.5 mg are escalation steps; 5 mg, 10 mg, and 15 mg are maintenance targets.

Reconstitution

  1. Swab vial tops with alcohol
  2. Draw 3.0 mL bacteriostatic water
  3. Inject slowly down vial wall (don't blast powder)
  4. Gently swirl - do not shake
  5. Rest 5-10 min to dissolve
  6. Refrigerate 2-8 C

Treatment duration

Continue the selected once-weekly maintenance target for the remaining planning period after escalation as long-term weekly maintenance.

Timing

Use the same day each week.

Support / expected effects

Side effects / tolerability

Practical tips

Storage

Refrigerated: ~45-60 days.

Notes / compatibility

Tirzepatide Screening Notes

Screening should follow clinician guidance and the approved-drug context for GLP-1/GIP medicines.

  • Personal or family history of medullary thyroid carcinoma (MTC) or MEN2: clinician review before use.
  • Prior pancreatitis: clinician review is needed.
  • Significant gallbladder disease or severe gallbladder events: clinician review is needed.
  • Severe GI disease, severe gastroparesis, or major motility issues: clinician review is needed.
  • Pregnancy, trying to conceive, or breastfeeding: avoid unless directed by a qualified clinician.
  • Diabetes medications, insulin, sulfonylureas, or hypoglycemia risk: clinician review because blood glucose can change.
  • Vomiting, diarrhea, or poor intake can raise dehydration risk; pause escalation and address fluids/electrolytes if this occurs.
  • Persistent tachycardia, palpitations, or unstable cardiovascular symptoms: clinician review before escalation.

Compatibility

Rule: only mix water-based peptides sharing the same diluent and timing intent. If unsure, keep separate.

FAQ

What titration schedule is shown for Tirzepatide?

Each vial card shows the same 15 mg weekly. Approved-label adult dose-escalation and maintenance context.

How does Tirzepatide titration work?

Start at 2.5 mg once weekly and follow the stages shown in the vial card. Escalation is not automatic. Hold the current dose longer when tolerability requires it. The 2.5 mg dose is for initiation; 7.5 mg and 12.5 mg are escalation steps; 5 mg, 10 mg, and 15 mg are maintenance targets.

What is the treatment-duration context for Tirzepatide?

Continue the selected once-weekly maintenance target for the remaining planning period after escalation as long-term weekly maintenance.

How are doses measured in syringe units here?

Units mean U-100 insulin-syringe gradations (1 mL = 100 units), not International Units. Use the conversion table for the selected vial format and confirm syringe and vial capacity.

Calculate the exact draw for TirzepatidePreloads the relevant vial format or fixed-ratio blend cycle.
Open calculator